Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

231.19
-0.2000-0.09%
Post-market: 231.190.00000.00%16:15 EDT
Volume:578.90K
Turnover:134.40M
Market Cap:15.01B
PE:15.80
High:235.54
Open:229.62
Low:227.00
Close:231.39
52wk High:266.38
52wk Low:128.80
Shares:64.91M
Float Shares:62.69M
Volume Ratio:0.71
T/O Rate:0.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.13
PE(LYR):-39.59

Loading ...

Jazz Pharmaceuticals is Maintained at Buy by Truist Securities

Dow Jones
·
3 hours ago

Jazz Pharmaceuticals price target raised to $286 from $281 at Truist

TIPRANKS
·
Yesterday

Jazz Pharma Director Bruce C. Cozadd Disposes of 6,000 Shares Worth $1,381,980

Reuters
·
Oct 06

ADPT, MRNA, CRWV, NBIS, JAZZ trending with analysts

TIPRANKS
·
Oct 03

Jazz Pharmaceuticals Initiated at Buy by Citigroup

Dow Jones
·
Sep 30

Jazz Pharmaceuticals Plc : Citigroup Initiates Coverage with Buy Rating; Target Price $325

THOMSON REUTERS
·
Sep 30

Citigroup Initiates Jazz Pharmaceuticals at Buy With $325 Price Target

MT Newswires Live
·
Sep 30

US Research Roundup-Alnylam Pharmaceuticals, Carvana, MongoDB

Reuters
·
Sep 30

Bernstein Reaffirms Their Hold Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Sep 26

Goldman Sachs Resumes Coverage with a Buy Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Sep 24

Jazz Reprices USD 1.9 Billion Term Loan, Extends Maturity to 2033

Reuters
·
Sep 24

Jazz Pharmaceuticals - Unit Enters Amendment No. 4 to Credit Agreement on Sept 23, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 24

Jazz Pharmaceuticals - Unit Borrows $273.31 Mln in Additional Tranche B-3 Dollar Term Loans - SEC Filing

THOMSON REUTERS
·
Sep 24

Nvidia, QIA-Backed Iambic Therapeutics Files for US IPO as Biotech Boom Rolls On

Reuters
·
Sep 22

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

THOMSON REUTERS
·
Sep 15

Jazz Pharmaceuticals Sees Meaningful Long-Term Value From Ziihera's Pursuits Beyond GEA, UBS Says

MT Newswires Live
·
Sep 12

Jazz Pharmaceuticals Price Target Raised to $337.00/Share from $315.00 by UBS

Dow Jones
·
Sep 11

UBS Adjusts Jazz Pharmaceuticals PT to $337 From $315, Maintains Buy Rating

MT Newswires Live
·
Sep 11

Jazz Pharmaceuticals Plc : UBS Raises Target Price to $337 from $315

THOMSON REUTERS
·
Sep 11

Jazz Pharma CEO Renee D. Gala Disposes of Ordinary Shares Worth $970,664.07

Reuters
·
Sep 11